Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 3
2000 9
2001 10
2002 25
2003 28
2004 35
2005 48
2006 65
2007 96
2008 60
2009 79
2010 67
2011 84
2012 90
2013 84
2014 70
2015 77
2016 73
2017 74
2018 68
2019 53
2020 26
Text availability
Article attribute
Article type
Publication date

Search Results

1,097 results
Results by year
Filters applied: . Clear all
Page 1
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Yatham LN, et al. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. Bipolar Disord. 2018. PMID: 29536616 Free PMC article.
Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first-line treatments for acute mania. First-line options for bipolar I depression include quetiapine, lurasidone p …
Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are reco …
Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium.
Ketter TA, Miller S, Dell'Osso B, Wang PW. Ketter TA, et al. J Affect Disord. 2016 Feb;191:256-73. doi: 10.1016/j.jad.2015.11.002. Epub 2015 Nov 25. J Affect Disord. 2016. PMID: 26688495 Review.
Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipolar disorder. ...Combination therapy including quetiapine and lithium was generally more effective than either agent alone in acute …
Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipola
Quetiapine for acute bipolar depression: a systematic review and meta-analysis.
Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Suttajit S, et al. Drug Des Devel Ther. 2014 Jun 25;8:827-38. doi: 10.2147/DDDT.S63779. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25028535 Free PMC article. Review.
BACKGROUND: Precise estimated risks and benefits of quetiapine for acute bipolar depression are needed for clinical practice. ...CONCLUSION: Quetiapine monotherapy is effective for acute bipolar depression and the prevention of mania/hypomania switchin …
BACKGROUND: Precise estimated risks and benefits of quetiapine for acute bipolar depression are needed for clinical practice. …
Quetiapine for insomnia: A review of the literature.
Anderson SL, Vande Griend JP. Anderson SL, et al. Am J Health Syst Pharm. 2014 Mar 1;71(5):394-402. doi: 10.2146/ajhp130221. Am J Health Syst Pharm. 2014. PMID: 24534594 Review.
As such, quetiapine is widely used off-label as a treatment for insomnia. Due to quetiapine's potential adverse effects, guidelines for the treatment of insomnia have recommended the drug's use only in patients with specific comorbid psychiatric disord …
As such, quetiapine is widely used off-label as a treatment for insomnia. Due to quetiapine's potential adverse effects …
Predictive modeling for response to lithium and quetiapine in bipolar disorder.
Kim TT, Dufour S, Xu C, Cohen ZD, Sylvia L, Deckersbach T, DeRubeis RJ, Nierenberg AA. Kim TT, et al. Bipolar Disord. 2019 Aug;21(5):428-436. doi: 10.1111/bdi.12752. Epub 2019 Feb 27. Bipolar Disord. 2019. PMID: 30729637
OBJECTIVES: Lithium and quetiapine are known to be effective treatments for bipolar disorder. However, little information is available to inform prediction of response to these medications. ...METHODS: Data (N = 482) were drawn from a randomized clinical trial of ou …
OBJECTIVES: Lithium and quetiapine are known to be effective treatments for bipolar disorder. However, little information is a …
A Pilot Study of the Effectiveness of Lithium Versus Quetiapine Immediate Release Monotherapy in Patients With Bipolar Spectrum Disorders.
Gao K, Goto T, Yuan C, Brownrigg B, Conroy C, Chan PK, Serrano MB, Ganocy SJ, Fang F, Calabrese JR. Gao K, et al. J Clin Psychopharmacol. 2018 Oct;38(5):422-434. doi: 10.1097/JCP.0000000000000927. J Clin Psychopharmacol. 2018. PMID: 30102627 Clinical Trial.
OBJECTIVE: The aim of this study was to compare the effectiveness of lithium versus quetiapine immediate release (IR) monotherapy in patients with bipolar I, II, or subthreshold bipolar disorder at any phase. ...CONCLUSIONS: The difference in effectiveness be …
OBJECTIVE: The aim of this study was to compare the effectiveness of lithium versus quetiapine immediate release (IR) monotherapy in …
Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Murasaki M, et al. Psychopharmacology (Berl). 2018 Oct;235(10):2859-2869. doi: 10.1007/s00213-018-4977-6. Epub 2018 Aug 1. Psychopharmacology (Berl). 2018. PMID: 30069587 Free PMC article. Clinical Trial.
RATIONALE: Quetiapine fumarate is an atypical antipsychotic indicated for various mental disorders, but it has not been studied in Japanese patients with bipolar depression. OBJECTIVES: To evaluate the efficacy and safety of quetiapine XR (extended rel …
RATIONALE: Quetiapine fumarate is an atypical antipsychotic indicated for various mental disorders, but it has not been studie …
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH, Calabrese JR, Kinrys G, Bobo WV, Singh V, Kamali M, Kemp D, Brody B, Reilly-Harrington NA, Sylvia LG, Shesler LW, Bernstein EE, Schoenfeld D, Rabideau DJ, Leon AC, Faraone S, Thase ME. Nierenberg AA, et al. J Clin Psychiatry. 2016 Jan;77(1):90-9. doi: 10.4088/JCP.14m09349. J Clin Psychiatry. 2016. PMID: 26845264 Clinical Trial.
METHOD: Within the duration of the study (September 2010-September 2013), participants with bipolar I or II disorder (DSM-IV-TR) were randomized for 6 months to receive lithium (n = 240) or quetiapine (n = 242). Lithium and quetiapine were combined with other …
METHOD: Within the duration of the study (September 2010-September 2013), participants with bipolar I or II disorder (DSM-IV-TR) were …
Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL).
Simon J, Geddes JR, Gardiner A, Rendell J, Goodwin GM, Mayer S. Simon J, et al. Bipolar Disord. 2018 Dec;20(8):733-745. doi: 10.1111/bdi.12713. Epub 2018 Dec 17. Bipolar Disord. 2018. PMID: 30375699 Free PMC article. Clinical Trial.
METHODS: Cost-utility analysis of the CEQUEL trial comparing quetiapine plus lamotrigine vs quetiapine monotherapy (and folic acid vs placebo in an add-on factorial design) for patients with bipolar depression (n = 201) from the health and social care perspec …
METHODS: Cost-utility analysis of the CEQUEL trial comparing quetiapine plus lamotrigine vs quetiapine monotherapy (and folic …
Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S, Murasaki M, Koyama T, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Kanba S, et al. BMC Psychiatry. 2019 Jun 26;19(1):198. doi: 10.1186/s12888-019-2181-9. BMC Psychiatry. 2019. PMID: 31242884 Free PMC article. Clinical Trial.
BACKGROUND: In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, quetiapine XR, demonstrated efficacy and safety in Japanese patients with bipolar depression. ...CONCLUSIONS: The efficacy of queti
BACKGROUND: In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, queti
1,097 results
Jump to page
Feedback